Clinical Trial

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

Recruiting
View on ClinicalTrials.gov →
Summary
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
Trial Details
NCT Number NCT06783816
Lead Sponsor Shanxi Bethune Hospital
Conditions Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
Enrollment 45 participants
Start Date 2023-12-01
Primary Completion 2028-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-20